Greenberg B, et al. - In patients with chronic heart failure and reduced ejection fraction, coronary artery disease, and sinus rhythm, researchers examined if adding low-dose rivaroxaban to background antiplatelet therapy impacted the risk for thromboembolic events. In this post hoc analysis of the COMMANDER HF multicenter, randomized, double-blind, placebo-controlled trial of 5,022 patients with CAD and worsening HF, thromboembolic events were not the major driver of the primary efficacy outcome, though, reduced risk of thromboembolic events was evident in correlation to the receipt of rivaroxaban vs placebo. It reduced the risk from 15.5% to 13.1% when sudden/unwitnessed deaths were included as part of the outcome and from 7.6% to 6.1% when sudden/unwitnessed deaths were not considered as part of the thromboembolic composite outcome.